<div id="readability-page-1"><p>Cumberland Pharmaceuticals (NASDAQ:CPIX - Get Free Report) released its quarterly earnings results on Tuesday. The specialty pharmaceutical company reported ($0.13) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.13), FiscalAI reports. Cumberland Pharmaceuticals had a positive return on equity of 5.04% and a negative net margin of 6.37%.The business had revenue of $9.13 million for the quarter, compared to the consensus estimate of $8.50 million.</p><p>Here are the key takeaways from Cumberland Pharmaceuticals' conference call:</p><ul>   <li>Cumberland signed a transformational deal with <strong>Apotex</strong> to sell its U.S. branded commercial portfolio for <strong>$100 million</strong> cash plus $9 million for inventory, transition fees and a milestone, which management says will materially strengthen the balance sheet and fund a shift to a development-focused strategy.</li>   <li>First‑quarter revenue from marketed brands was $9.1 million (up ~5% excluding a prior one‑time milestone), with a GAAP net loss of ~$3.3 million and an adjusted loss of $1.9 million ($0.13/share); operating cash flow was positive $387,000 and cash on hand was $11 million.</li>   <li>The clinical pipeline, led by <strong>ifetroban</strong>, shows progress—~1,400 subjects dosed, FDA <strong>Fast Track</strong> plus Orphan/Rare Pediatric designations for Duchenne muscular dystrophy, completed enrollment in scleroderma, and ongoing IPF trials with an interim safety review clearing continuation and interim efficacy expected later this year.</li>   <li>Commercial and manufacturing wins include FDA expanded labeling for <strong>Caldolor</strong> (post‑operative pain), FDA clearance of the manufacturing site enabling a planned <strong>Vaprisol</strong> relaunch this year, launch of Talicia sales promotion, and the first shipment of Vibativ to China—moves management says will broaden patient access prior to the portfolio sale.</li> </ul><h2>Cumberland Pharmaceuticals Trading Up 0.4%</h2><p>Shares of CPIX traded up $0.02 during trading hours on Tuesday, hitting $4.55. The company had a trading volume of 318,892 shares, compared to its average volume of 787,554. The firm has a market cap of $68.07 million, a P/E ratio of -23.95 and a beta of -0.06. The stock's 50 day moving average price is $3.45 and its 200 day moving average price is $3.42. The company has a quick ratio of 0.84, a current ratio of 1.01 and a debt-to-equity ratio of 0.21. Cumberland Pharmaceuticals has a 52-week low of $1.85 and a 52-week high of $6.26. </p><h2>Institutional Inflows and Outflows</h2><p>Several large investors have recently modified their holdings of the stock. Perceptive Advisors LLC purchased a new position in shares of  Cumberland Pharmaceuticals in the fourth quarter worth about $1,358,000.  Marshall Wace LLP purchased a new position in shares of  Cumberland Pharmaceuticals in the fourth quarter worth about $192,000.  Geode Capital Management LLC increased its holdings in shares of  Cumberland Pharmaceuticals by 5.6% in the fourth quarter. Geode Capital Management LLC now owns 107,274 shares of the specialty pharmaceutical company's stock worth $427,000 after buying an additional 5,653 shares during the period.  Two Sigma Investments LP increased its holdings in shares of  Cumberland Pharmaceuticals by 16.5% in the third quarter. Two Sigma Investments LP now owns 37,591 shares of the specialty pharmaceutical company's stock worth $117,000 after buying an additional 5,326 shares during the period.  Finally, Dimensional Fund Advisors LP increased its holdings in shares of  Cumberland Pharmaceuticals by 11.1% in the third quarter. Dimensional Fund Advisors LP now owns 280,869 shares of the specialty pharmaceutical company's stock worth $876,000 after buying an additional 27,980 shares during the period. Hedge funds and other institutional investors own  15.51% of the company's stock. </p><h2>Wall Street Analysts Forecast Growth</h2><p>A number of equities research analysts have weighed in on the company. Wall Street Zen upgraded Cumberland Pharmaceuticals from a &#34;hold&#34; rating to a &#34;buy&#34; rating in a research report on Saturday, March 14th. Weiss Ratings  restated a &#34;sell (d-)&#34; rating on shares of Cumberland Pharmaceuticals in a research report on Friday, March 27th. One equities research analyst  has rated the stock with a Sell rating,  According to MarketBeat, Cumberland Pharmaceuticals  has an average rating of &#34;Sell&#34;.</p><p><b>Get Our Latest Analysis on CPIX</b></p><h2>Cumberland Pharmaceuticals Company Profile</h2> (Get Free Report)<p>Cumberland Pharmaceuticals Inc <span>NASDAQ: CPIX<span></span></span> is a specialty pharmaceutical company based in Nashville, Tennessee, focused on the development, manufacture and commercialization of hospital and acute care products. Founded in 1993, the company has built a portfolio of branded therapeutics designed to address critical care needs in emergency medicine, critical care units and other hospital settings. Cumberland's strategy emphasizes in-licensing and acquiring products that have established safety and efficacy profiles but limited market reach, then leveraging its sales network to expand their commercial footprint.  </p><p>The company's flagship products include Acetadote (N-acetylcysteine injection), the only FDA-approved antidote for acetaminophen overdose administered intravenously; Vasostrict (vasopressin injection), used to raise blood pressure in adults with vasodilatory shock; Cerebrex (diclofenac sodium injection), an anti-inflammatory agent for managing acute pain and fever; and Dynastat (parecoxib sodium), a COX-2 inhibitor for postoperative pain relief.</p><h2>Further Reading</h2><ul><li>Five stocks we like better than Cumberland Pharmaceuticals</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q1BJWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="325" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q1BJWA"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Cumberland Pharmaceuticals Right Now?</h2><p>Before you consider Cumberland Pharmaceuticals, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cumberland Pharmaceuticals wasn't on the list.</p><p>While Cumberland Pharmaceuticals currently has a Sell rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

CPIX

<p>Cumberland Pharmaceuticals (NASDAQ:CPIX) reported earnings of ($0.13) per share, meeting analysts' expectations. The company generated $9.13 million in revenue, surpassing the $8.50 million estimate. Cumberland signed a $100 million deal with Apotex to sell its U.S. branded portfolio, enhancing its balance sheet. The firm has a positive return on equity of 5.04% and a negative net margin of 6.37%. Shares rose 0.4% to $4.55, with institutional investors increasing their stakes. Analysts have mixed ratings, with one upgrade to "buy" and an average rating of "sell."</p>

Cumberland Pharmaceuticals (NASDAQ:CPIX) Issues Earnings Results